{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:41:44Z","timestamp":1779356504037,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2952,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The SHIFT trial showed that ivabradine reduced heart rate (HR) and the risk of cardiovascular outcomes. Concerns remain over the efficacy and safety of ivabradine on heart failure (HF) due to Chagas disease (ChD). We therefore conducted a post hoc analysis of the SHIFT trial to investigate the effect of ivabradine in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>SHIFT was a randomized, double-blind, placebo-controlled trial in symptomatic systolic stable HF, HR \u2265 70 b.p.m., and in sinus rhythm. The ChD HF subgroup included 38 patients, 20 on ivabradine, and 18 on placebo. The ChD HF subgroup showed high prevalence of bundle branch right block and, compared with the overall SHIFT population, lower systolic blood pressure; higher use of diuretics, cardiac glycosides, and antialdosterone agents; and lower use of angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker or target daily dose of beta-blocker. ChD HF presented a poor prognosis (all-cause mortality at 2 years was ~60%). The mean twice-daily dose of ivabradine was 6.26 \u00b1 1.15 mg and placebo 6.43 \u00b1 1.55 mg. Ivabradine reduced HR from 77.9 \u00b1 3.8 to 62.3 \u00b1 10.1 b.p.m. (P = 0.005) and improved functional class (P = 0.02). A trend towards reduction in all-cause death was observed in ivabradine arm vs. placebo (P = 0.07). Ivabradine was not associated with serious bradycardia, atrioventricular block, hypotension, or syncope.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ChD HF is an advanced form of HF with poor prognosis. Ivabradine was effective in reducing HR in these patients and improving functional class. Although our results are based on a very limited sample and should be interpreted with caution, they suggest that ivabradine may have a favourable benefit\u2013risk profile in ChD HF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12240","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T04:26:53Z","timestamp":1513744013000},"page":"249-256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety Profile and Efficacy of Ivabradine in Heart Failure Due to Chagas Heart Disease: A\n                    <i>Post Hoc<\/i>\n                    Analysis of the SHIFT Trial"],"prefix":"10.1093","volume":"5","author":[{"given":"Edimar Alcides","family":"Bocchi","sequence":"first","affiliation":[{"name":"Heart Institute (InCor), S\u00e3o Paulo University Medical School (HC-FUMSP) , Rua Dr Melo Alves 690, 4o andar, Bairro Cerqueira Cesar, S\u00e3o Paulo, S\u00e3o Paulo, CEP 014170-010 ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Rassi","sequence":"additional","affiliation":[{"name":"Medical School, Federal University of Goi\u00e1s , Goi\u00e2nia, Goi\u00e1s ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Veiga","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Heart Institute (InCor), S\u00e3o Paulo University Medical School (HC-FUMSP) , Rua Dr Melo Alves 690, 4o andar, Bairro Cerqueira Cesar, S\u00e3o Paulo, S\u00e3o Paulo, CEP 014170-010 ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"2026012115114132300_ehf212240-bib-0001","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/hrt.2008.151225","article-title":"Cardiomyopathy, adult valve disease and heart failure in South America","volume":"95","author":"Bocchi","year":"2009","journal-title":"Heart"},{"key":"2026012115114132300_ehf212240-bib-0002","article-title":"Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy","volume":"7","author":"Mart\u00ed-Carvajal","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012115114132300_ehf212240-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0066-782X2012001000001","article-title":"Updating of the Brazilian guideline for chronic heart failure\u20142012","volume":"98","author":"Bocchi","year":"2012","journal-title":"Arq Bras Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0004","first-page":"1","article-title":"I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy","volume":"97","author":"Andrade","year":"2011","journal-title":"Arq Bras Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0005","first-page":"3","article-title":"III Brazilian guidelines on chronic heart failure","volume":"93","author":"Bocchi","year":"2009","journal-title":"Arq Bras Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0006","first-page":"1","article-title":"I Latin American guidelines for the assessment and management of decompensated heart failure","volume":"85","author":"Bocchi","year":"2005","journal-title":"Arq Bras Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"RANDOMIZED TRIAL OF BENZNIDAZOLE FOR CHRONIC CHAGAS' CARDIOMYOPATHY","volume":"373","author":"Morillo","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115114132300_ehf212240-bib-0008","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(10)61372-4","article-title":"Antitrypanosomal agents: treatment or threat?","volume":"376","author":"Issa","year":"2010","journal-title":"Lancet"},{"key":"2026012115114132300_ehf212240-bib-0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCHEARTFAILURE.109.882035","article-title":"Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial","volume":"3","author":"Issa","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026012115114132300_ehf212240-bib-0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jacc.2013.06.013","article-title":"The reality of heart failure in Latin America","volume":"62","author":"Bocchi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026012115114132300_ehf212240-bib-0012","first-page":"III","article-title":"Chronotropic incompetence in Chagas disease: usefulness of dual sensor pacemaker based on volume minute and accelerometer","volume":"30","author":"Pach\u00f3n","year":"2015","journal-title":"Rev Bras Cir Cardiovasc"},{"key":"2026012115114132300_ehf212240-bib-0013","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/01.CIR.96.6.2031","article-title":"Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts","volume":"96","author":"Farias de Oliveira","year":"1997","journal-title":"Circulation"},{"key":"2026012115114132300_ehf212240-bib-0014","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/0735-1097(95)00262-2","article-title":"High prevalence of antibodies against beta 1- and beta 2-adrenoceptors in patients with primary electrical cardiac abnormalities","volume":"26","author":"Chiale","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1540-8167.1994.tb01174.x","article-title":"Antibodies to \u03b21-adrenergic receptors disclosing agonist-like properties in idiopathic dilated cardiomyopathy and Chagas' heart disease","volume":"5","author":"Rosenbaum","year":"1994","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026012115114132300_ehf212240-bib-0016","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/eurjhf\/hfq124","article-title":"Exercise training in Chagas' cardiomyopathy: trials are welcome for this neglected heart disease","volume":"12","author":"Bocchi","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026012115114132300_ehf212240-bib-0017","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0002-8703(96)90358-0","article-title":"In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease","volume":"131","author":"Bellotti","year":"1996","journal-title":"Am Heart J"},{"key":"2026012115114132300_ehf212240-bib-0018","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.healun.2016.06.005","article-title":"Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Lofrano-Alves","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2026012115114132300_ehf212240-bib-0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2012.12.147","article-title":"Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis","volume":"431","author":"Li","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"2026012115114132300_ehf212240-bib-0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039394","article-title":"Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis","volume":"7","author":"Yue-Chun","year":"2012","journal-title":"PLoS One"},{"key":"2026012115114132300_ehf212240-bib-0021","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fphar.2016.00408","article-title":"The protective effects of ivabradine in preventing progression from viral myocarditis to dilated cardiomyopathy","volume":"7","author":"Yue-Chun","year":"2016","journal-title":"Front Pharmacol"},{"key":"2026012115114132300_ehf212240-bib-0022","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6949320","article-title":"Impact of ivabradine on inflammatory markers in chronic heart failure","volume":"2016","author":"Rohm","year":"2016","journal-title":"J Immunol Res"},{"key":"2026012115114132300_ehf212240-bib-0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/ALN.0000000000001431","article-title":"Ivabradine attenuates the microcirculatory derangements evoked by experimental sepsis","volume":"126","author":"Miranda","year":"2017","journal-title":"Anesthesiology"},{"key":"2026012115114132300_ehf212240-bib-0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00392-016-1024-7","article-title":"Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study","volume":"106","author":"Mangiacapra","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115114132300_ehf212240-bib-0026","first-page":"523","article-title":"Update on indications and results of the surgical treatment of heart failure","volume":"63","author":"Bocchi","year":"1994","journal-title":"Arq Bras Cardiol"},{"key":"2026012115114132300_ehf212240-bib-0027","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1053-2498(00)00235-7","article-title":"The Brazilian experience with heart transplantation: a multicenter report","volume":"20","author":"Bocchi","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"2026012115114132300_ehf212240-bib-0028","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12240","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/5\/3\/249\/66137092\/eschf_5_3_249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/5\/3\/249\/66137092\/eschf_5_3_249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:15:31Z","timestamp":1769026531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/5\/3\/249\/8403800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,12,20]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12240","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2017,12,20]]},"assertion":[{"value":"2017-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}